- Home
- RDI vs IOBT Comparison
RDI vs IOBT Comparison
Compare RDI & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | IOBT |
|---|---|---|
| Founded | 1937 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 26.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDI | IOBT |
|---|---|---|
| Price | $1.06 | $0.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 23.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.21 |
| 52 Week High | $1.65 | $2.79 |
Technical Indicators
Market Signals| Indicator | RDI | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 41.87 |
| Support Level | $1.00 | $0.32 |
| Resistance Level | $1.16 | $0.40 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 25.00 | 53.47 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.